Skip to main content
Susan (Coleman (Married Name)) Hubbard, MD, Pediatrics, Dallas, TX, Texas Health Presbyterian Hospital Dallas

SusanJeanne(Coleman (Married Name))HubbardMD

Pediatrics Dallas, TX

Physician

Dr. Hubbard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hubbard's full profile

Already have an account?

Education & Training

  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Pediatrics, 1983 - 1984
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsResidency, Pediatrics, 1981 - 1983
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 1981

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1981 - 2024
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Alpha Omega Alpha 1981
  • Super Doctor SuperDoctors.com
  • Fellow (FAAP) American Academy of Pediatrics

Publications & Presentations

Other

Press Mentions

  • Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerSeptember 17th, 2021
  • Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
    Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 5th, 2021
  • Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
    Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver CancerJune 28th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations